Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;8(11):722.
doi: 10.21037/atm.2020.01.119.

Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum

Kok Pin Yong  1   2   3 , Ho Jin Kim  3
Affiliations
Editorial

Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum

Kok Pin Yong et al. Ann Transl Med. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.01.119). HJK has received a grant from the National Research Foundation of Korea; received consultancy/speaker fees from Alexion, Celltrion, Eisai, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok, and Viela Bio; serves on a steering committee for MedImmune/Viela Bio; is a co-editor for the Multiple Sclerosis Journal and an associated editor for the Journal of Clinical Neurology. KPY has no conflicts of interest to declare.

Comment on

References

    1. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol 2019;15:53-8. 10.1038/s41582-018-0082-z - DOI - PubMed
    1. Winkelmann A, Loebermann M, Reisinger EC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016;12:217-33. 10.1038/nrneurol.2016.21 - DOI - PubMed
    1. Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2019. [Epub ahead of print]. - PMC - PubMed
    1. Wijnands JMA, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 2018;89:1050-56. 10.1136/jnnp-2017-317493 - DOI - PubMed
    1. Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 2018;1:e184169. 10.1001/jamanetworkopen.2018.4169 - DOI - PMC - PubMed